Voclosporin Effective in Lupus Nephritis Results from AURA-LV trial in patients with active disease

The AURA-LV trial assessed voclosporin, a calcineurin inhibitor, in patients with active lupus nephritis and found that low-dose voclosporin may be successfully added to mycophenolate mofetil and corticosteroids to control active lupus nephritis. A total of 265 lupus nephritis patients were enrolled from 79 worldwide centers in this phase II, randomized, double-blind, placebo-controlled trial of two doses of voclosporin (23.7 mg or 39.5 mg, given twice daily) versus placebo in patients already taking mycophenolate and steroids. The primary endpoint was complete renal response at 24 weeks, and the secondary endpoint was complete renal response at 48 weeks. https://www.medpagetoday.com/rheumatology/lupus/76476?xid=nl_mpt_DHE_2018-11-26&eun=g721819d0r&pos=1&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%202018-11-26&utm_term=Daily%20Headlines%20-%20Active%20User%20-%20180%20days